Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs 10X Genomics Inc — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $81.11, while 10X Genomics Inc trades at $57.7 (market cap $7.61B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, iShares Core MSCI Emerging Markets ETF nearer its low. Which is the better fit depends on your goals.
| IEMG | TXG | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $58.57 |
52-Week Low | $61.76 | $11.34 |
Market Cap | — | $7.61B |
Enterprise Value | — | $7.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $81.02, up 1.84% today with a bullish technical signal from moving averages. The ETF shows strong momentum with 35% returns over the past year, driven by emerging market exposure and a 40% technology weighting focused on AI themes. Recent news highlights IEMG's outperformance versus developed market ETFs and its competitive 0.09% expense ratio.
Outlook remains positive given emerging market growth potential and AI-driven tech exposure, though risks include concentration in volatile emerging economies and elevated RSI levels suggesting potential near-term consolidation. The ETF's valuation discount to US equities and strong institutional inflows support continued investor interest.
TXG trades at $57.77, down 1.37% today, with a bullish technical outlook supported by moving averages and strong support at $55. The company shows improving fundamentals with Q2 2026 earnings beating estimates and positive cash flow trends, though it remains unprofitable with negative margins. Recent news highlights collaborations with major medical institutions and strategic acquisitions expanding multiomics capabilities.
Investment outlook is mixed: technical strength and analyst upgrades suggest near-term upside potential, but high valuation multiples and persistent losses pose significant risks. The stock faces pressure from competitive threats and execution challenges in achieving profitability, requiring careful monitoring of upcoming Q3 earnings and revenue growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
